{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:46:23Z","timestamp":1770507983522,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T00:00:00Z","timestamp":1147132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      To examine the significance of the thymus and the neutralization of interleukin\u20102 (IL\u20102) in treating renal cancer, as the involvement of immunoregulatory cells in tumour development\n                      <jats:italic>in vivo<\/jats:italic>\n                      is well known, naturally occurring CD25\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells possess potent immunoregulatory functions, and they are of thymic origin dependent on IL\u20102.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      We first tested activity against mouse renal cell carcinoma (RENCA) cells by adoptively transferring splenocytes of euthymic Balb\/c mice depleted of CD25\n                      <jats:sup>+<\/jats:sup>\n                      cells into athymic Balb\/c nude mice bearing established macroscopic RENCA tumours. Second, we tested the anti\u2010RENCA activity in euthymic mice bearing macroscopic RENCA tumours by neutralizing IL\u20102.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The intravenous administration of CD25\n                      <jats:sup>+<\/jats:sup>\n                      cell\u2010depleted splenocytes of euthymic Balb\/c mice initiated the retardation of macroscopic RENCA tumours subcutaneously established in athymic Balb\/c mice. The tumour site showed massive lymphocyte infiltration of mainly CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells. By eliminating either the CD4\n                      <jats:sup>+<\/jats:sup>\n                      cells, CD8\n                      <jats:sup>+<\/jats:sup>\n                      cells, or natural killer (NK) cells with antibodies after the adoptive transfer of CD25\n                      <jats:sup>+<\/jats:sup>\n                      cell\u2010depleted splenocytes of euthymic Balb\/c mice, macroscopic RENCA tumour retardation was abrogated. The growth of macroscopic RENCA tumour established in euthymic Balb\/c mice was also retarded with IL\u20102 neutralization alone by anti\u2010IL\u20102 monoclonal antibody (mAb), as well as co\u2010administration of anti\u2010IL\u20102 mAb and anti\u2010CD25 mAb compared with that of the controls given vehicle. After tumour inoculation, peri\u2010 and intratumoral infiltration of CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells was very prominent in RENCA tumours in hosts given anti\u2010IL\u20102 mAb, regardless of the administration of anti\u2010CD25 mAb. Two\u2003\u00d7\u200310\n                      <jats:sup>5<\/jats:sup>\n                      units of recombinant human IL\u20102 reverted the retardation of RENCA tumour growth caused by the anti\u2010IL\u20102 mAb. IL\u20102 neutralization alone in euthymic Balb\/c mice with no tumour inoculation did not suppress splenic CD25\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Both the intravenous administration of CD25\n                      <jats:sup>+<\/jats:sup>\n                      cell\u2010depleted splenocytes of euthymic Balb\/c mice into athymic Balb\/c nude mice and IL\u20102 blocking with anti\u2010IL\u20102 mAb in euthymic Balb\/c mice retarded the growth of macroscopic RENCA tumours\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06180.x","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T09:20:39Z","timestamp":1147166439000},"page":"1314-1321","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neutralization of interleukin\u20102 retards the growth of mouse renal cancer"],"prefix":"10.1111","volume":"97","author":[{"given":"HIROSHI","family":"FUKUHARA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKIHIKO","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TADAICHI","family":"KITAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKUMI","family":"TAKEUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.3.1151"},{"key":"e_1_2_8_3_2","first-page":"3128","article-title":"Tumor rejection by in vivo administration of anti\u2010CD25 (interleukin\u20102 receptor alpha) monoclonal antibody","volume":"59","author":"Onizuka S","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.10.5211"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-4096.2004.04876.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.161.1.72"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.4.371"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00415.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80067-O"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830251111"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240144"},{"key":"e_1_2_8_12_2","first-page":"3.1.1","volume-title":"Current Protocol in Immunology","author":"Coligan TJ","year":"1991"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050347"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1006\/clin.1996.0190"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041982"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804303381805"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06180.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06180.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:09:49Z","timestamp":1761739789000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06180.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,9]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06180.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06180.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,9]]},"assertion":[{"value":"2006-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}